2015
DOI: 10.1016/j.jaad.2014.11.024
|View full text |Cite
|
Sign up to set email alerts
|

A systematic review of topical corticosteroid withdrawal (“steroid addiction”) in patients with atopic dermatitis and other dermatoses

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1

Citation Types

6
145
1
9

Year Published

2016
2016
2024
2024

Publication Types

Select...
9
1

Relationship

0
10

Authors

Journals

citations
Cited by 159 publications
(161 citation statements)
references
References 38 publications
6
145
1
9
Order By: Relevance
“…Due to the chronic and chronically relapsing nature of AD there can be a lifelong need for treatment, with a significant risk of adverse events. These include skin atrophy, and to a lesser extent striae and telangiectasias, while the risk of a rebound phenomenon when tapering TCSs is exaggerated if used appropriately [24,25]. The risk of systemic side effects is low and correlated to the potency of the TCS, the extent and degree of skin inflammation, and the age of the patient.…”
Section: Topical Therapiesmentioning
confidence: 99%
“…Due to the chronic and chronically relapsing nature of AD there can be a lifelong need for treatment, with a significant risk of adverse events. These include skin atrophy, and to a lesser extent striae and telangiectasias, while the risk of a rebound phenomenon when tapering TCSs is exaggerated if used appropriately [24,25]. The risk of systemic side effects is low and correlated to the potency of the TCS, the extent and degree of skin inflammation, and the age of the patient.…”
Section: Topical Therapiesmentioning
confidence: 99%
“…An additional concern with prolonged or inappropriate use of TCSs is a condition known as TCS withdrawal (32,33). Alternatively known as topical corticosteroid-induced rosacea-like dermatitis, topical steroid-dependent face, or red skin syndrome, TCS withdrawal is a condition that involves the exacerbation of AD symptoms after discontinuation of TCS treatment (26,33,34).…”
Section: Topical Corticosteroidsmentioning
confidence: 99%
“…The structure of skin in these areas, characterized by a thin epidermis, extensive vascularization or many epidermal appendages and nerve endings, causes it to be more absorbent [20,69]. Therefore, TCS should not be used under occlusion in these areas [4,20,49,67], and patients prescribed TCS should be closely monitored [20,72,73] and educated about proper uses [16].…”
Section: Topical Corticosteroidsmentioning
confidence: 99%